Clinical Trial Update: Effect of CYP3A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetic study evaluated how CYP3A genetic polymorphisms affect atorvastatin exposure and metabolism in patients with coronary heart disease. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Heart Disease

Drugs mentioned

• atorvastatin (atorvastatin)

Snippet

Sponsor: Liuhuaqiao Hospital | Conditions: Coronary Heart Disease | Phase 1 | Status: COMPLETED